Argent BioPharma Forms Strategic Manufacturing Alliance in Malta

Argent BioPharma Ltd (ASX: RGT), a clinical-stage biopharmaceutical company focused on neuroimmune therapeutics, has entered into a 49-year strategic collaboration with David Trading Ltd. The agreement grants David Trading exclusive operational control over Argent’s EU-GMP-certified Malta facility, originally commissioned in May 2023 for CimetrA® production. David Trading will assume full financial and managerial responsibility, reducing Argent's annual operational costs by up to USD $1 million. CimetrA production will continue on a cost-plus-25% basis, with plans to introduce additional products upon regulatory clearance. The partnership also includes an irrevocable purchase option for David Trading to acquire 100% of the facility’s shares for USD $1 million. This deal not only ensures uninterrupted manufacturing but also opens avenues for future contract manufacturing operations and expanded product lines. The collaboration reflects Argent's broader strategy to enhance efficiency and unlock new revenue streams through strategic outsourcing and facility optimization.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com